Company to present at Rodman and Renshaw Global Investment Conference in New York City on Sept 12, 2017 WILMINGTON, Del., Sept. 6, 2017 /PRNewswire/ — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug […]

Recent hospitalization is a risk factor for further suicide attempts — potentially related to patient care perceptions WILMINGTON, Del.–(BUSINESS WIRE)– NeuroRx launches the first global “Voice of the Patient Survey” for those diagnosed with bipolar disorder, in collaboration with leading patient advocacy groups, mental health advocates and expert opinion leaders. The strictly anonymous survey, seeking […]

Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression Wilmington, Delaware , March 24, 2017 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that Jonathan Javitt, M.D., M.P.H., Chief Executive Officer, […]

Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression Wilmington, Delaware , March 20, 2017 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that Jonathan Javitt, M.D., M.P.H., Chief Executive Officer, […]

Company developing NRX-101 – first potential treatment for Acute Suicidal Ideation in Bipolar Depression Wilmington, Delaware & Tel Aviv, Israel , Feb. 10, 2017 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that Jonathan Javitt, Ph.D., M.D., Chief Executive Officer, […]

Clinical stage biopharma company advances development of first-in-class drug to decrease the risk of suicide in those suffering from bipolar depression SAN FRANCISCO, Jan. 4, 2017 /PRNewswire/ — Biotech Showcase at the JP Morgan Healthcare Conference NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB) in Bipolar […]

Company with research operations in US and Israel seeks to develop first-in-class drug to decrease the risk of suicide in those suffering from depression WILMINGTON, Del. and TEL AVIV, Israel, Oct. 18, 2016 /PRNewswire/ — NeuroRx, a clinical-stage pharmaceutical company developing NRX-101 (CycluradTM), a first-in-class potentially breakthrough oral drug for the treatment of Acute Suicidal Ideation in […]

WILMINGTON, Del. and HAIFA, Israel, Sept 7, 2016 /PRNewswire/ — NeuroRx, a clinical-stage pharmaceutical company developing CycluradTM, a first-in-class, potentially breakthrough drug for the prevention of suicide in bipolar depression, announced today that it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., […]

Company with research operations in US and Israel seeks to develop first-in-class drug to decrease the risk of suicide in those suffering from depression TEL AVIV, Israel–(BUSINESS WIRE)– NeuroRx, a clinical-stage pharmaceutical company developing a first-in-class potentially breakthrough drug for the prevention of suicide in bipolar depression, was awarded first prize in the annual startup […]

Findings note the transient nature of ketamine effects and paucity of promising experimental NMDA antagonists WILMINGTON, Delaware, October 21, 2015 /PRNewswire/ — The active ingredient of Cyclurad™ by NeuroRx, Inc has been identified as potentially promising in the treatment of depression in this month’s report by the American Psychiatric Association Task Force on Novel Biomarkers […]